<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Sticking it to the VC Man: Johnny Stine Builds Biotech Startup on a Shoestring</title>
	<atom:link href="http://www.xconomy.com/seattle/2009/02/06/sticking-it-to-the-vc-man-johnny-stine-builds-biotech-startup-on-a-shoestring/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2009/02/06/sticking-it-to-the-vc-man-johnny-stine-builds-biotech-startup-on-a-shoestring/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 03:54:18 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Antibody Industry Week in Review &#124; 2.20.09 — The Antibody Blog</title>
		<link>http://www.xconomy.com/seattle/2009/02/06/sticking-it-to-the-vc-man-johnny-stine-builds-biotech-startup-on-a-shoestring/comment-page-1/#comment-46867</link>
		<dc:creator>Antibody Industry Week in Review &#124; 2.20.09 — The Antibody Blog</dc:creator>
		<pubDate>Fri, 20 Feb 2009 05:15:30 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=11777#comment-46867</guid>
		<description>[...] Timmerman at Xconomy profiles Johnny Stine, an entrepreneur who brings biotech bootstrapping to a completely new level at North [...]</description>
		<content:encoded><![CDATA[<p>[...] Timmerman at Xconomy profiles Johnny Stine, an entrepreneur who brings biotech bootstrapping to a completely new level at North [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Carl Weissman</title>
		<link>http://www.xconomy.com/seattle/2009/02/06/sticking-it-to-the-vc-man-johnny-stine-builds-biotech-startup-on-a-shoestring/comment-page-1/#comment-46280</link>
		<dc:creator>Carl Weissman</dc:creator>
		<pubDate>Sat, 14 Feb 2009 06:36:08 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=11777#comment-46280</guid>
		<description>Stickin&#039; it to the VC Man?  I am not so sure.  Different businesses require different business plans.  Some of those business plans support venture capital backing, others are more appropriate for angel investors, and some work best when they are bootstrapped by the founders.

In addition, those different business types also require different characteristics of the folks that found, run, and work in them.  

Few people may know or remember this, but the company currently called Life Technologies was bootstrapped out of a garage, largely by a guy named Joe Fernandez who long ago left the company.  They were profitable early and stayed that way, scaling their business as they went along.  

Johnny has found a business that he can bootstrap.  Johnny has the guts, determination, and personality to roll up his sleeves, dig in, and not only be the guy isolating antibodies but also the guy who is hanging sheetrock, mudding, and painting.  

His is not a business that would work well for traditional venture capital.  And he knows it (and maybe revels in it...).  Google Ger van den Engh and his company Cytopeia that he built in basically a &quot;garage&quot; in north Seattle.  His company got purchased by Becton-Dicksenson for what I promise you was a significant amount of money (I know Ger, and I know he would never give up his independence unless it was an offer he could not refuse).  Cytopeia was also a business not easily suited to traditional venture capital, although I am sure his angel investors did very well.

Who knows if Johnny&#039;s company North Coast Biologics can become the next Life Technologies.  Or the next Cytopeia.  But as I said months ago, I would not bet against Johnny.

But stickin&#039; it to the VC man?  I don&#039;t think so.  Johnny has found a business model where VC&#039;s should not get involved.  And it suits him well.  Good for him.  We should all be so lucky.</description>
		<content:encoded><![CDATA[<p>Stickin’ it to the VC Man?  I am not so sure.  Different businesses require different business plans.  Some of those business plans support venture capital backing, others are more appropriate for angel investors, and some work best when they are bootstrapped by the founders.</p>
<p>In addition, those different business types also require different characteristics of the folks that found, run, and work in them.  </p>
<p>Few people may know or remember this, but the company currently called Life Technologies was bootstrapped out of a garage, largely by a guy named Joe Fernandez who long ago left the company.  They were profitable early and stayed that way, scaling their business as they went along.  </p>
<p>Johnny has found a business that he can bootstrap.  Johnny has the guts, determination, and personality to roll up his sleeves, dig in, and not only be the guy isolating antibodies but also the guy who is hanging sheetrock, mudding, and painting.  </p>
<p>His is not a business that would work well for traditional venture capital.  And he knows it (and maybe revels in it…).  Google Ger van den Engh and his company Cytopeia that he built in basically a “garage” in north Seattle.  His company got purchased by Becton-Dicksenson for what I promise you was a significant amount of money (I know Ger, and I know he would never give up his independence unless it was an offer he could not refuse).  Cytopeia was also a business not easily suited to traditional venture capital, although I am sure his angel investors did very well.</p>
<p>Who knows if Johnny’s company North Coast Biologics can become the next Life Technologies.  Or the next Cytopeia.  But as I said months ago, I would not bet against Johnny.</p>
<p>But stickin’ it to the VC man?  I don’t think so.  Johnny has found a business model where VC’s should not get involved.  And it suits him well.  Good for him.  We should all be so lucky.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Improvisations &#171; MIT Sloan Management Review &#187; News from the start-up scene</title>
		<link>http://www.xconomy.com/seattle/2009/02/06/sticking-it-to-the-vc-man-johnny-stine-builds-biotech-startup-on-a-shoestring/comment-page-1/#comment-46105</link>
		<dc:creator>Improvisations &#171; MIT Sloan Management Review &#187; News from the start-up scene</dc:creator>
		<pubDate>Fri, 13 Feb 2009 00:41:48 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=11777#comment-46105</guid>
		<description>[...] reports on a biotech start-up that has launched without outside investors &#8211; in a sector where that&#8217;s tough to do. (The entrepreneur instead obtained research [...]</description>
		<content:encoded><![CDATA[<p>[...] reports on a biotech start-up that has launched without outside investors – in a sector where that’s tough to do. (The entrepreneur instead obtained research [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Farah R</title>
		<link>http://www.xconomy.com/seattle/2009/02/06/sticking-it-to-the-vc-man-johnny-stine-builds-biotech-startup-on-a-shoestring/comment-page-1/#comment-46009</link>
		<dc:creator>Farah R</dc:creator>
		<pubDate>Thu, 12 Feb 2009 05:45:28 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=11777#comment-46009</guid>
		<description>What a lovely heartwarming story in these recessionary times. I love this guy. All the best Mr. Stine.</description>
		<content:encoded><![CDATA[<p>What a lovely heartwarming story in these recessionary times. I love this guy. All the best Mr. Stine.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

